TABLE 3.
Drug | Target | Line |
Erlotinib | EGFR sensitising mutation | 1 |
Gefitinib | EGFR sensitising mutation | 1 |
Afatinib | EGFR sensitising mutation | 1 |
Osimertinib | EGFR T790M mutation | 1+ |
Crizotinib | ALK/ROS1 | 1 |
Ceritinib | ALK | 2 |
Dabrafenib+trametinib | BRAF | 1 |
EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase.